Print Page  Close Window

Investor Center Home
Corporate Profile
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.

More >>

BLCM (Common Stock)
(US Dollar)
Price$9.16
Change0.00
(%)Volume (0.00%)0
ExchangeNASDAQ
Data as of 12/11/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
12/11/17Bellicum Pharmaceuticals Announces Presentations of its Controllable Switch Technology Platform at the American Society of Hematology 2017 Annual MeetingPrinter Friendly Version
12/09/17Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant with BPX-501 in Children with Blood Cancers and Nonmalignant DiseasesPrinter Friendly Version
11/08/17Bellicum Pharmaceuticals to Present at the Jefferies 2017 London Healthcare ConferencePrinter Friendly Version
11/07/17Bellicum Reports Third Quarter 2017 Financial ResultsPrinter Friendly Version
More >>
Upcoming Events
12/09/17
through
12/11/17
Presentation Details for ASH 2017

BPX-501:

Oral Presentation:“Donor T Cells Genetically Modified with a Novel Suicide Gene (Inducible Caspase 9, iC9) Expand and Persist Over Time After Post-Allograft Infusion in Patients Given αβ T-Cell and B-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (αβ Haplo-HSCT) Contributing to Accelerate Immune Recovery”
Abstract Number: 211
Session Name: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Prevention
Session Date: Saturday, December 9, 2017
Session Time: 2:00 p.m. - 3:30 p.m. EST
Presentation Time: 2:00 p.m. EST

Controllable Switch Technology:

Poster Presentation: “Dual-Switch CAR-T Cells: Orthogonal Molecular Switches to Control Activation and Elimination of CAR-T Cells to Target CD123+ Cancer”
Abstract Number: 3184
Session Name: 703. Adoptive Immunotherapy: Poster II
Date: Sunday, December 10, 2017
Presentation Time: 6:00 p.m. - 8:00 p.m. EST

Poster Presentation: “Inducible MyD88/CD40 (iMC) Costimulation Enhances Polyclonal Epstein-Barr Virus-Specific Cytotoxic T Lymphocyte (EBV-CTL) Proliferation and Anti-Tumor Activity” Abstract Number: 3337
Session Name: 801. Gene Therapy and Transfer: Poster II
Date: Sunday, December 10, 2017
Presentation Time: 6:00 p.m. - 8:00 p.m. EST

Poster Presentation: “MyD88/CD40 Enhanced CD19-Specific CAR-T Cells Maintain Therapeutic Efficacy Following Resolution of Cytokine-Related Toxicity Using Inducible Caspase-9”
Abstract Number: 4615
Session Name: 801. Gene Therapy and Transfer: Poster III
Date: Monday, December 11, 2017
Presentation Time: 6:00 p.m. - 8:00 p.m. EST

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources